Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism
eLife · 2025
DOI: 10.7554/elife.101888 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Weijie Wu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Program for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University Inter…. Hauptthemen laut MEDLINE: Tamoxifen, Drug Resistance, Neoplasm, Breast Neoplasms, Antineoplastic Agents, Hormonal. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China, Peking University Health Science Center.
Abstract (Originalsprache)
Approximately 40% ERα-positive breast cancer patients suffer from therapeutic resistance to tamoxifen. Although reduced ERα level is the major cause of tamoxifen resistance, the underlying mechanisms remain elusive. Here, we report that FRMD8 raises the level of ERα at both transcriptional and post-translational layers. FRMD8 deficiency in MMTV-Cre + ; Frmd8 fl/fl ; PyMT mice accelerates mammary tumor growth and loss of luminal phenotype, and confers tamoxifen resistance. Single-cell RNA profiling reveals that Frmd8 loss decreases the proportion of hormone-sensing differentiated epithelial cells and downregulates the levels of ERα. Mechanically, on one hand, loss of FRMD8 inhibits ESR1 transcription via suppressing the expression of FOXO3A, a transcription factor of ESR1 . On the other hand, FRMD8 interacts both with ERα and UBE3A, and disrupts the interaction of UBE3A with ERα, thereby blocking UBE3A-mediated ERα degradation. In breast cancer patients, FRMD8 gene promoter is found hypermethylated and low level of FRMD8 predicts poor prognosis. Therefore, FRMD8 is an important regulator of ERα and may control therapeutic sensitivity to tamoxifen in ERα-positive breast cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology,…
- Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory for Digestive Health; National Clinical Research Center for Digestive Diseases, Beijing, China.
- Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Educa…
- Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, China.
ORCID-Profile: Weijie Wu, Miao Yu, Hongquan Zhang
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
- Peking University Health Science Center
- Postdoctoral Fellowship Program of CPSF
Zitieren
APA
Wu, W., Yu, M., Li, Q., Zhao, Y., Zhang, L., Sun, Y., Wang, Z., Gong, Y., Wang, W., Liu, C., Zhang, J., Tang, Y., Xu, X., Guo, X., Zhan, J., & Zhang, H. (2025). Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism. eLife. https://doi.org/10.7554/elife.101888
Vancouver
Wu W, Yu M, Li Q, Zhao Y, Zhang L, Sun Y, et al. Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism. eLife. 2025. doi:10.7554/elife.101888
BibTeX
@article{Wu2025,
author = {Wu, Weijie and Yu, Miao and Li, Qianchen and Zhao, Yiqian and Zhang, Lei and Sun, Yi and Wang, Zhenbin and Gong, Yuqing and Wang, Wenjing and Liu, Chenying and Zhang, Jing and Tang, Yan and Xu, Xiaojie and Guo, Xiaojing and Zhan, Jun and Zhang, Hongquan},
title = {Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.101888}
}
EUVIMED